Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABIOOTCMKTS:BGMDOTCMKTS:GWHPOTCMKTS:IPSEY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABIOARCA biopharma$384.99$1.56▼$4.49$34.82M0.91607,995 shs290,800 shsBGMDBG Medicine$0.00$0.00▼$0.00N/A2.58250 shsN/AGWHPGlobal Wholehealth Partners$0.00$0.00▼$0.00N/AN/AN/AN/AIPSEYIPSEN$29.34-2.5%$28.88$25.11▼$32.25$9.84B0.541,300 shs726 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABIOARCA biopharma0.00%0.00%0.00%0.00%-99.50%BGMDBG Medicine0.00%0.00%0.00%-23.08%0.00%GWHPGlobal Wholehealth Partners0.00%0.00%0.00%0.00%0.00%IPSEYIPSEN0.00%-1.05%0.00%-1.08%-10.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABIOARCA biopharmaN/AN/AN/AN/AN/AN/AN/AN/ABGMDBG MedicineN/AN/AN/AN/AN/AN/AN/AN/AGWHPGlobal Wholehealth PartnersN/AN/AN/AN/AN/AN/AN/AN/AIPSEYIPSENN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABIOARCA biopharma 0.00N/AN/AN/ABGMDBG Medicine 0.00N/AN/AN/AGWHPGlobal Wholehealth Partners 0.00N/AN/AN/AIPSEYIPSEN 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest IPSEY, ABIO, BGMD, and GWHP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025IPSEYIPSENDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABIOARCA biopharmaN/AN/AN/AN/A$2.25 per shareN/ABGMDBG MedicineN/AN/AN/AN/AN/AN/AGWHPGlobal Wholehealth Partners$10K0.00N/AN/AN/ANaNIPSEYIPSEN$3.87B2.54N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABIOARCA biopharma-$5.34M-$0.42N/AN/AN/AN/A-20.18%-19.51%N/ABGMDBG MedicineN/AN/A0.00N/AN/AN/AN/AN/AN/AGWHPGlobal Wholehealth Partners-$5.16MN/A0.00N/AN/AN/AN/AN/AN/AIPSEYIPSEN$374.30MN/A0.0010.19N/AN/AN/AN/A7/31/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABIOARCA biopharmaN/AN/AN/AN/AN/ABGMDBG MedicineN/AN/AN/AN/AN/AGWHPGlobal Wholehealth PartnersN/AN/AN/AN/AN/AIPSEYIPSEN$0.260.89%N/AN/AN/ALatest IPSEY, ABIO, BGMD, and GWHP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/3/2025IPSEYIPSEN$0.28960.97%6/9/20256/10/20256/25/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABIOARCA biopharmaN/A26.6126.61BGMDBG MedicineN/AN/AN/AGWHPGlobal Wholehealth PartnersN/AN/AN/AIPSEYIPSENN/A1.341.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABIOARCA biopharma56.44%BGMDBG MedicineN/AGWHPGlobal Wholehealth PartnersN/AIPSEYIPSENN/AInsider OwnershipCompanyInsider OwnershipABIOARCA biopharma30.90%BGMDBG Medicine6.50%GWHPGlobal Wholehealth Partners10.30%IPSEYIPSENN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABIOARCA biopharma614.51 million10.02 millionOptionableBGMDBG Medicine5N/AN/ANot OptionableGWHPGlobal Wholehealth Partners6143.88 million129.07 millionNot OptionableIPSEYIPSEN5,325335.26 millionN/ANot OptionableIPSEY, ABIO, BGMD, and GWHP HeadlinesRecent News About These CompaniesIpsen S.A. (OTCMKTS:IPSEY) Short Interest Down 45.5% in MayJune 15, 2025 | marketbeat.comIpsen (OTCMKTS:IPSEY) Shares Pass Above 200 Day Moving Average - Time to Sell?June 11, 2025 | marketbeat.comIpsen S.A. (OTCMKTS:IPSEY) Announces Dividend Increase - $0.29 Per ShareJune 3, 2025 | marketbeat.comShort Interest in Ipsen S.A. (OTCMKTS:IPSEY) Declines By 26.7%June 2, 2025 | marketbeat.comIpsen S.A. - Initiation of the share buy-back programJune 2, 2025 | globenewswire.comIpsen (OTCMKTS:IPSEY) Shares Cross Above 200-Day Moving Average - What's Next?May 30, 2025 | marketbeat.comIpsen (OTCMKTS:IPSEY) Stock Passes Above Two Hundred Day Moving Average - Here's WhyMay 23, 2025 | marketbeat.comIpsen S.A. - Annual General Meeting held on 21 May 2025May 21, 2025 | globenewswire.comGENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in ItalyMay 20, 2025 | globenewswire.comNew data highlights the impact of Iqirvo on fatigue, says IpsenMay 7, 2025 | thepharmaletter.comIpsen Appoints EVP, Strategy & TransformationMay 6, 2025 | contractpharma.comIpsen Pharma: Ipsen appoints Laura Réveillon as EVP, Strategy & TransformationMay 6, 2025 | finanznachrichten.deIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General MeetingApril 30, 2025 | globenewswire.comIpsen launches seventh Service HUB to support heat treatment industry in Texas regionApril 28, 2025 | pim-international.comIpsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitisApril 25, 2025 | pmlive.comIpsen delivers strong sales in the first quarter of 2025April 17, 2025 | thepharmaletter.comIpsen's liver disease drug Iqirvo off to promising launch in battle with Gilead's LivdelziApril 17, 2025 | fiercepharma.comIpsen S.A. (IPSEY) Q1 2025 Earnings Call TranscriptApril 16, 2025 | seekingalpha.comIpsen delivers strong sales in the first quarter 2025 and confirms its full-year guidanceApril 16, 2025 | markets.businessinsider.comIpsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitisApril 8, 2025 | pmlive.comIpsen publishes its 2024 Universal Registration DocumentApril 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSEY, ABIO, BGMD, and GWHP Company DescriptionsARCA biopharma NASDAQ:ABIOARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.BG Medicine OTCMKTS:BGMDBG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.Global Wholehealth Partners OTCMKTS:GWHPGlobal WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.IPSEN OTCMKTS:IPSEY$29.34 -0.77 (-2.54%) As of 06/18/2025 03:32 PM EasternIpsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
